Arrayit Corporation (ARYC)

[Alyssa]

OK, I said, "Makes me wonder..." That is misleading? lol OK then. Anyone who knows anything about Arrayit and its technology should be "wondering" too because the similarities could be more than just a coincidence. And give me a break, I have not "suggested" anything.

There is no indication anywhere that their technology is in dispute. You cannot make that assumption because their first attempt placed them on the FDA's "pre-emergency use authorization" list, which clearly indicates the FDA was expecting a follow-up or improved test from Arrayit.

Please give readers of this board a little credit. They're not stupid, you know, and would not invest in a company because someone is "wondering." That is just silly.

If Arrayit received 100% proficiency scores from the third party, independent lab, American College of Pathologists, for their allergy and asthma tests, then why couldn't they achieve the same for their Covid-19 test or tests? Also, it should be remembered that Arrayit received Medicare Part B approval for those very allergy/asthma tests. So no, I don't think the technology is in dispute.

Arrayit Corporation Scores 100% on Proficiency Testing Conducted by the College of American Pathologists...

"Sunnyvale, CA, May 16, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company scored 100% on clinical laboratory proficiency testing conducted by the College of American Pathologists (CAP). Arrayit received a perfect score in highly quantitative measurements of immunoglobulin E (IgE), the antibodies in the human bloodstream indicative of allergy and asthma. The CAP SA2018 Diagnostic Immunology Survey proficiency test included 1,677 clinical laboratories utilizing IgE testing equipment manufactured by major corporations in the life sciences, molecular diagnostics and pharmaceutical markets. CAP, the international proficiency testing leader, ensures and improves healthcare quality by fostering clinical excellence through the impartial and carefully-supervised proficiency testing process.

Arrayit uses its patented and proprietary microarray technology to accurately and rapidly test IgE levels in patient blood card specimens shipped to its Silicon Valley clinical laboratory by hospitals, health maintenance organizations (HMOs), clinical laboratories, insured patients in physician groups, and consumers through the assistance of a medical doctor. Arrayit leverages miniaturization, allergen and sample multiplexing, and a high degree of robotic and software automation to deliver test results quickly and non-invasively using finger stick blood sampling."

https://www.marketscreener.com/quote/stock/ARRAYIT-CORPORATION-120792591/news/Arrayit-Corporation-Scores-100-on-Proficiency-Testing-Conducted-by-the-College-of-American-Patholog-26596357/